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RESPIRATORY DISEASES/DISORDERS—Clinical
Outcomes
PRP4
INHALED ANTIINFLAMMATORY MEDICATION
USE AND SUBSEQUENT HOSPITALIZATIONS
AMONG TEXAS MEDICAID PATIENTS WITH
PERSISTENT ASTHMA
Smith M, Rascati K
The University of Texas, Austin,TX, USA
The National Heart Lung and Blood Institute (NHBLI)
recommends the use of inhaled anti-inﬂammatory 
medications (inhaled corticosteroids, inhaled cromolyn,
or inhaled nedocromil) for patients with persistent
asthma. OBJECTIVE: The purpose of the study was to
investigate the effect of inhaled anti-inﬂammatory med-
ications on subsequent inpatient hospital events, while
controlling for demographic and resources use variables.
METHODS: Medication and medical service records
were extracted for Texas Medicaid patients who were
classiﬁed as having persistent asthma based on criteria set
by the National Committee for Quality Assurance
(NCQA). A historical cohort design was used. An
asthma-related hospitalization (with no previous hospi-
talization for a least six months before) served as the
index event. Patients were then followed until a subse-
quent hospitalization occurred or until one-year past their
index event. Outcomes of patient who had at least 1 pre-
scription for an inhaled anti-inﬂammatory within 100
days of their index hospitalization were compared with
patients who did not have any records of these types of
medications for one year following their index event.
Logistic regression was used to compare the two groups
while controlling for other factors. RESULTS: There were
728 persistent asthma patients in the exposed group
(those with inhaled anti-inﬂammatory use within 100
days) compared to 981 without exposure to these types
of medications. Controlling for age, gender, ethnicity, and
previous resource use, those in the exposed group had 32
percent reduction in the risk of a subsequent hospitaliza-
tion in the year following their index hospitalization (RR
= 0.681, p = 0.017, 95% CI 0.497–0.933). CONCLU-
SIONS: For patients categorized as persistent asthmatics,
less than half received anti-inﬂammatory medications (as
recommended by the NHBLI) within the ﬁrst 100 days
after their index asthma-related hospitalization. Patients 
who did receive these medications had a lower risk of a
subsequent asthma-related hospitalization for the next
year.
PRP5
EPIDEMIOLOGICAL STUDY ESTIMATING THE
PREVALENCE OF ACUTE SINUSITIS AND
ACUTE EXACERBATION OF CHRONIC
SINUSITIS IN GERMANY
Elies W1, Thate-Waschke IM2, Bestehorn M3, König A2,
Evers T2
1Staedtische Krankenanstalten Bielefeld, Bielefeld, Germany;
2Bayer Vital GmbH, Leverkusen, Germany; 3TNS EMNID,
Pullach, Germany
OBJECTIVES: The epidemiology of acute sinusitis 
and acute exacerbation of chronic sinusitis (AECS) is still
unknown in Germany. This study aims to make an 
estimate of the prevalence of acute sinusitis and AECS in
Germany. METHODS: A representative sample of 63
GPs and 40 ear, nose and throat specialists have been
asked to document all patients older than 16 years with
acute sinusitis or AECS appearing in their practice over 
a period of one week (during the time frame from 
February 2nd to April 1st, 2001). Afterwards, an expan-
sion for Germany has been calculated/estimated.
RESULTS: Overall, 2,250 patients suffering from acute
sinusitis or AECS has been documented in 8 weeks. One
thousand one hundred eighty-seven patients visited a GP
and 1,063 patients visited an ear, nose and throat 
specialist. Eighty percent of patients suffered from 
acute sinusitis, whilst 20% had an acute exacerbation of
chronic sinusitis. On the average, each GP treated 19
sinusitis patients per week, i.e. 9% of total patients 
visiting the practice. An ear, nose and throat specialist
treated 27 patients per week, which means 11% of his
total patients. Based on the assumption that 67.5 million
people older than 16 years live in Germany (2001), there
are approximately 1.215.000 sinusitis patients per week,
i.e. 1.8% of German population having a sinusitis and
seeing their GP in an average winter week. CONCLU-
SIONS: Assuming at least 20 weeks of wintertime 
(from November to March), there are approximately
24.300.000 sinusitis patients in Germany within this time
frame. This means hardly one third of German popula-
tion. When interpreting this result it is important to take
into account that sinusitis is a disease with repeating 
exacerbations.
RESPIRATORY DISEASES/DISORDERS—Quality of
Life
PRP6
ASSESSMENT OF RESPIRATORY DISEASE
SEVERITY USING POSTAL QUESTIONNAIRES
Hazell ML, Frank TL, Frank PI
North West Lung Research Centre, Manchester, UK
OBJECTIVES: To assess the severity of obstructive
airways disease using a postal questionnaire and to
examine correlations between healthcare utilisation/cost
and disease severity. METHOD: A postal survey was 
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conducted among general practice patients who were
deﬁned as likely to have obstructive airways disease on
the basis of a previous postal respiratory questionnaire.
The six-item severity questionnaire was based on the
GINA guidelines and considered symptom frequency and 
intensity. Individuals were categorised into one of four
severity groups. Healthcare utilisation events and cost of
care (over six months) for the four groups were com-
pared. RESULTS: Disease was classiﬁed as intermittent in
52.9%, mild persistent in 27.2%, moderate persistent in
12.9% and severe persistent in 7.1%. The six items 
of the severity questionnaire were strongly correlated
(Spearman’s rho 0.56–0.80, p < 0.001 throughout), 
suggesting measurement of a single construct. Severity
classiﬁcation using the questionnaire was signiﬁcantly
correlated with healthcare utilisation and cost. In general,
those categorised as having the most severe disease had
at least double the healthcare utilisation of those with
least severe disease, with mean total cost over 6 months
increasing from £428.55 (least severe) to £1,431.50 (most
severe) (p < 0.001 for correlation). CONCLUSIONS:
This short postal questionnaire will provide a useful 
categorisation of obstructive airways disease severity in
large scale epidemiological studies.
PRP7
HEALTH RELATED QUALITY OF LIFE (HRQOL)
IN ASTHMA PATIENTS IN RELATIONSHIP TO
ASTHMA SEVERITY DEGREE
Rebollo P1, Ferrer M1, Serra-Batlles J2, Plaza V3, Morejon E4,
Alonso J1
1Institut Municipal d’Investigació Mèdica (IMIM-IMAS); Hospital
Central de Asturias, Barcelona, Spain; 2Hospital General de
Vic, Barcelona, Spain; 3Hospital de Sant Pau, Barcelona, Spain;
4GlaxoSmithKline España, Madrid, Spain
OBJECTIVES: The main objective of present study was
to evaluate the discriminatory ability of the HRQOL 
in relationship to severity degree in asthma patients.
METHODS: Cross-sectional descriptive study carried out
in a semirural county of 110.000 inhabitants. Patients
were included in stable asthma phase, and classiﬁed into
three groups: mild, moderate, and severe. Assessment
included spirometry, sociodemographic, clinical data
(morbidity and use of health-services), and two HRQOL
questionnaires: one generic, the Nottingham Health
Proﬁle (NHP), and one speciﬁc, the St. George’s 
Respiratory Questionnaire (SGRQ). HRQOL scores were
standardized by age and gender according to Spanish
population norms. RESULTS: Out of 385 patients with
asthma, 52 were excluded because different reasons, and
333 adult patients were included with a mean age of 42
years (64% were females). Patients were classiﬁed accord-
ing to asthma severity degree: mild, 140 patients (42%),
moderate, 116 patients (35%), and severe, 77 patients
(23%). Median time of evolution of asthma was 8 years,
and most of patients (80.1%) had less than 3 asthma
attacks per year. NHP mean (SD) standardized score was
0.20 (1.21) for mild patients, 0.68 (1.43) moderate, and
1.21 (1.57) severe. SGRQ mean standardized score (SD)
was 2.75 (2.11) for mild patients, 3.61 (2.31) moderate,
and 4.17 (2.44) severe. Although patients with mild
asthma had low impaired FEV1, and NHP scores close
to that of general population, they showed substantial
effects on HRQOL using the speciﬁc instrument, the
SGRQ. CONCLUSIONS: Both HRQOL instruments are
associated to asthma severity degree but discriminatory
ability was higher for the disease-speciﬁc instrument. In
addition, SGRQ seems to be more useful than NHP and
traditional clinical measures identifying the mild severity
degree impact.
PRP8
QUALITY OF LIFE AND COSTS FOR MODERATE
AND SEVERE ASTHMA IN FRANCE
Lafuma A1, Brun-Strang C2, Leynadier F3, Grimfeld A4,
Everhard F5
1CEMKA-EVAL, Bourg La Reine, France; 2Novartis-Pharma,
Rueil-Malmaison, France; 3Hôpital Tenon, Paris, France; 4Hôpital
Trousseau, Paris, France; 5Novartis Pharmaceuticals AG, Basel,
Switzerland
OBJECTIVE: To evaluate clinical ﬁgures, quality of life
and costs of moderate or severe asthma patients in France
METHODS: A cross sectional study was carried out in a
sample of French patients included by allergologists.
Patients presenting moderate or severe asthma using
NHBLI criteria were included. Clinical information and
Quality of Life (AQLQ) were collected at the day of the
visit. Resource utilization was collected retrospectively
except for drug treatments that were collected prospec-
tively. Statistical analyses compare patients according to
their severity of asthma and level of disease control and
attempt to highlight risk factors for hospitalisations and
asthma control. Costs were valued according to French
recommendations. RESULTS: 211 patients were included
and analysed of whom 32.1% of severe and 67.9% of
moderate asthma. Controlled patients were 35.1% and
64.9% of the patients were not controlled (at least one
acute episode during the previous year). There are statis-
tical differences in clinical ﬁgures, Quality of Life and
resources utilization between controlled and uncontrolled
patients, as well as, on uncontrolled patients, between
those hospitalized and those not. Annual cost of uncon-
trolled hospitalised patients is three times higher than
costs of ambulatory patients uncontrolled and 4 times
higher than controlled patients. Patient’s hospitalisations
can be predicted by the level of night-time symptoms and
level of quick relief treatment as well as asthma control
can be predicted by the level and frequency of exacerba-
tions and the level of severity assessed by physicians.
CONCLUSION: Uncontrolled asthma is responsible for
high costs. There is a need for a treatment able to better
control asthma, to increase Quality of Life of the patients
and decrease directs costs.
